The CRISPR Licensing Landscape

@LSPN May 3-4th, 2023, Boston MA

Contact Michael.Arciero@ersgenomics.com for more information.

favicon-300x300

ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology.
 Our founder, Dr. Emmanuelle Charpentier  won the Nobel Prize the discovery of CRISPR/Cas9 in 2020. 

CRISPR/Cas9 has transformed the field of gene editing. At ERS, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.
 

Michael Arciero, VP IP & Commercial Development with ERS Genomics will speak at this year’s Life Sciences Patent Network (LSPN) in Boston, May 3-4. 

Attend this session to understand:

1. The current CRISPR Licensing Landscape

2. Common misperceptions: Fact vs. Fction

3. The patent batttle – what’s next?

4. Do you need a license?

5. Regional differences – what geolocation means for your licensing requirements.


CRISPR/Cas9 is a patented invention, so any commerical use requires a license. Despite the confusion caused by several high-profile patent interference cases, the patent landscape is clearer than you might think.

Contact Michael.Arciero@ersgenomics.com to secure your CRISPR/Cas9 license.

 

Schedule time with:

Michael Arciero, Vice President IP & Commercial Development

‘This is a lot of misinformation in circulation when it comes to the CRISPR licensing landscape. In speaking at LSPN, my goal is to cut through the noise and provide straightforward answers to common misperceptions.’

Schedule a Meeting

Licensing

Learn More

Intellectual Property

Learn More

Knowledge Centre

Learn More

Contact US

Learn More

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

CRISPR-GPT — The Future of Bioengineering

Merging CRISPR Gene Editing with Agentic AI   A new AI co-pilot automates genome engineering, accelerating discovery and democratizing CRISPR expertise.    Introduction: The Convergence of Two Powerful Technologies  Two of the most transformative technologies of our era, CRISPR/Cas9 gene editing and large language models (LLMs), are converging to reshape.

Read Full Article

A Year Since BIO

One Year On: The Future of CRISPR is Now  As I prepare for my second BIO-International Convention as CEO of ERS Genomics, I’ve taken a moment to reflect on the extraordinary year behind us. CRISPR’s practical impact is accelerating, enabling breakthroughs in treating genetic diseases, engineering more resilient crops, and.

Read Full Article

CVC successfully appeals prior CRISPR U.S. patent decision

U.S. Court of Appeals rules that the PTAB applied the wrong legal standard for conception in the CRISPR-Cas9 interference dispute with the Broad Institute.  Decision sent back to the PTAB for reconsideration under the correct legal standard for assessing the inventor of CRISPR-Cas9 gene editing in eukaryotic cells.    Dublin,.

Read Full Article